Condition or disease | Intervention/treatment | Phase |
---|---|---|
Prostate Cancer Prostate Adenocarcinoma Prostate Neoplasm Prostate Cancer Metastatic Castration-resistant Prostate Cancer | Drug: Talazoparib Drug: Temozolomide | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 55 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects With Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair |
Actual Study Start Date : | July 11, 2019 |
Estimated Primary Completion Date : | July 2023 |
Estimated Study Completion Date : | July 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Metastatic Castration Resistant Prostate Cancer
Participants have Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
|
Drug: Talazoparib
Phase I maximum tolerated dose portion: Level 1, 2, 3 - 1 mg QD Days 1-6 Level 4, 5 - 1.25 mg QD Days 1-6 Level 6 - 1.5 mg QD Days 1-6 Other Name: Tala
Drug: Temozolomide Phase I maximum tolerated dose portion: Level 1 - 37.5 mg/m2 QD Days 2-8 Level 2 - 75 mg/m2 QD Days 2-8 Level 3 & 4 - 100 mg/m2 QD Days 2-8 Level 5 & 6 - 125 mg/m2 QD Days 2-8 Other Name: TMZ
|
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
NOTE: HIPAA authorization may be either included in the informed consent or obtained separately
Documented progressive mCRPC based on at least one of the following criteria:
Absolute neutrophil count (ANC): >/= 1,500/ul Hemoglobin: >/= 9g/dL Platelet count: >/= 100,00/ul Creatinine: >/= 60 mL/min estimated using the Cockcroft-Gault equation Potassium: >/= 3.5 mmol/L (within institutional normal range) Bilirubin: </= 1.5 ULN (unless documented Gilbert's disease) SGOT(AST): </= 2.5 x ULN SGPT (ALT): </= 2.5 x ULN
Exclusion Criteria:
Note, if testing is germline negative, somatic testing is still required. If the subject is germline positive, the subject in ineligible.
Contact: Karen Autio, MD | 646-422-4632 | AutioK@mskcc.org | |
Contact: Howard Scher, MD | 646-888-4878 | scherh@mskcc.org |
United States, New Jersey | |
Memoral Sloan Kettering Basking Ridge (Limited Protocol Activities) | Recruiting |
Basking Ridge, New Jersey, United States, 07920 | |
Contact: Karen Autio, MD 646-422-4632 | |
Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Recruiting |
Montvale, New Jersey, United States, 07645 | |
Contact: Karen Autio, MD 646-422-4632 | |
United States, New York | |
Memorial Sloan Kettering Commack (Limited protocol activity) | Recruiting |
Commack, New York, United States, 11725 | |
Contact: Karen Autio, MD 646-422-4632 | |
Memoral Sloan Kettering Westchester (Limited Protocol Activities) | Recruiting |
Harrison, New York, United States, 10604 | |
Contact: Karen Autio, MD 646-422-4632 | |
Memorial Sloan Kettering Cancer Center | Recruiting |
New York, New York, United States, 10065 | |
Contact: Karen Autio, MD 646-422-4632 | |
Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Recruiting |
Uniondale, New York, United States, 11553 | |
Contact: Karen Autio, MD 646-422-4632 | |
United States, Virginia | |
University of Virginia | Recruiting |
Charlottesville, Virginia, United States, 22908 | |
Contact: Michael Devitt, MD 434-924-9333 | |
United States, Wisconsin | |
University of Wisconsin | Recruiting |
Madison, Wisconsin, United States, 53792 | |
Contact: Christos Kyriakopoulos, MD 608-263-0786 |
Principal Investigator: | Karen Autio, MD | Memorial Sloan Kettering Cancer Center |
Tracking Information | |||||||||
---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | July 11, 2019 | ||||||||
First Posted Date ICMJE | July 15, 2019 | ||||||||
Last Update Posted Date | June 10, 2021 | ||||||||
Actual Study Start Date ICMJE | July 11, 2019 | ||||||||
Estimated Primary Completion Date | July 2023 (Final data collection date for primary outcome measure) | ||||||||
Current Primary Outcome Measures ICMJE |
|
||||||||
Original Primary Outcome Measures ICMJE |
|
||||||||
Change History | |||||||||
Current Secondary Outcome Measures ICMJE | Not Provided | ||||||||
Original Secondary Outcome Measures ICMJE | Not Provided | ||||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||||
Descriptive Information | |||||||||
Brief Title ICMJE | A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer | ||||||||
Official Title ICMJE | A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Subjects With Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair | ||||||||
Brief Summary | The purpose of this study is to determine what the safest dose of talazoparib plus temozolomide for participants with metastatic castration resistant prostate cancer. | ||||||||
Detailed Description | Not Provided | ||||||||
Study Type ICMJE | Interventional | ||||||||
Study Phase ICMJE | Phase 1 Phase 2 |
||||||||
Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||||
Condition ICMJE |
|
||||||||
Intervention ICMJE |
|
||||||||
Study Arms ICMJE | Experimental: Metastatic Castration Resistant Prostate Cancer
Participants have Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage Repair
Interventions:
|
||||||||
Publications * | Not Provided | ||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||
Recruitment Information | |||||||||
Recruitment Status ICMJE | Recruiting | ||||||||
Estimated Enrollment ICMJE |
55 | ||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||
Estimated Study Completion Date ICMJE | July 2023 | ||||||||
Estimated Primary Completion Date | July 2023 (Final data collection date for primary outcome measure) | ||||||||
Eligibility Criteria ICMJE |
Inclusion Criteria:
NOTE: HIPAA authorization may be either included in the informed consent or obtained separately
Absolute neutrophil count (ANC): >/= 1,500/ul Hemoglobin: >/= 9g/dL Platelet count: >/= 100,00/ul Creatinine: >/= 60 mL/min estimated using the Cockcroft-Gault equation Potassium: >/= 3.5 mmol/L (within institutional normal range) Bilirubin: </= 1.5 ULN (unless documented Gilbert's disease) SGOT(AST): </= 2.5 x ULN SGPT (ALT): </= 2.5 x ULN
Exclusion Criteria:
Note, if testing is germline negative, somatic testing is still required. If the subject is germline positive, the subject in ineligible.
|
||||||||
Sex/Gender ICMJE |
|
||||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||||
Accepts Healthy Volunteers ICMJE | No | ||||||||
Contacts ICMJE |
|
||||||||
Listed Location Countries ICMJE | United States | ||||||||
Removed Location Countries | |||||||||
Administrative Information | |||||||||
NCT Number ICMJE | NCT04019327 | ||||||||
Other Study ID Numbers ICMJE | 19-041 | ||||||||
Has Data Monitoring Committee | Not Provided | ||||||||
U.S. FDA-regulated Product |
|
||||||||
IPD Sharing Statement ICMJE |
|
||||||||
Responsible Party | Memorial Sloan Kettering Cancer Center | ||||||||
Study Sponsor ICMJE | Memorial Sloan Kettering Cancer Center | ||||||||
Collaborators ICMJE | Not Provided | ||||||||
Investigators ICMJE |
|
||||||||
PRS Account | Memorial Sloan Kettering Cancer Center | ||||||||
Verification Date | June 2021 | ||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |